A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...
Pharmaceutical start-up AIRNA has raised $90 million in an oversubscribed series A financing round. The firm aims to produce drugs that edit RNA transcripts in the body. AIRNA obtained an initial $30 ...
Healthcare Asia Magazine on MSN
HKU develop RNA 'cut-and-patch' tool for treating neurodegenerative diseases
It enables precise removal and replacement of faulty RNA segments without changing DNA. Researchers from the School of ...
Beijing Zhongke Journal Publising Co. Ltd. This study is led by Professor Zhenghe Li (State Key Laboratory of Rice Biology and breeding, Institute of Biotechnology, Zhejiang University, Hangzhou, ...
A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...
Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
In a recent study in Nature Communications, researchers examined the adenosine-to-inosine (A-to-I) nucleoside editing of postmortem and live prefrontal cortical tissues. Researchers found that RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results